There is a high manufacturing demand to constrain global ingredients, partnering options, and available CDMO capacity, though continued growth in pharma sales and innovation bode well for supply side companies and CDMOs.
In a report outlining predictions for the coming year, the organization advises industry professionals to brace themselves for supply chain challenges.